Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.
Rezensionen / Stimmen
"This book explores major breakthroughs in the drug treatment of sleep disorders. . The intended audience is scientists, clinicians, and drug developers. . With its specific aim of providing an extensive update on drug treatment for sleep disorders, this book is helpful contribution to sleep medicine." (M. Isabel L. Crisostomo, Doody's Book Reviews, July, 2015)
Reihe
Sprache
Verlagsort
Verlagsgruppe
Springer International Publishing
Illustrationen
9
14 farbige Abbildungen, 9 s/w Abbildungen
VIII, 297 p. 23 illus., 14 illus. in color.
Dateigröße
ISBN-13
978-3-319-11514-6 (9783319115146)
DOI
10.1007/978-3-319-11514-6
Schweitzer Klassifikation
